BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201219
DTSTAMP:20260515T132440
CREATED:20200930T094828Z
LAST-MODIFIED:20210118T080755Z
UID:27309-1605657600-1608335999@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:As well as the physical CPhI & P-MEC China 2020 show that will take place in Shanghai from 16th – 18th December\, a digital extension of the event – known as “Virtual Expo Connect” – will take place online from November 18th – December 18th\, allowing you to do business in China\, no matter your location. The hybrid “Virtual Expo Connect” offers an online alternative for international visitors unable to travel to the physical show in China due to travel restrictions\, adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nCPhI & P-MEC China Virtual Expo Connect\nA hybrid offline-2-online platform for global pharma professionals\nNov 18 – Dec 18\, 2020 \nTo know more about CPhI & P-MEC China Virtual Expo Connect please click here.
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect/
LOCATION:Virtual Event powered by CPhI China & Pharmasources.com
CATEGORIES:e
ORGANIZER;CN="CPhI China & Pharmasources.com":MAILTO:yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201130
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132440
CREATED:20200715T082010Z
LAST-MODIFIED:20200817T082502Z
UID:26329-1606694400-1607039999@www.pharmajournalist.com
SUMMARY:2nd Annual Gene Therapy Analytical Development | Running Digitally for 2020
DESCRIPTION:Optimizing Analytical Methods to Guarantee Safe\, High Quality\, Consistent & Efficacious Gene Therapy Products \nIn the context of rapid gene therapy progress and mounting regulatory scrutiny\, the 2nd Annual Gene Therapy Analytical Development Summit will virtually unite large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific conference will unite the Analytical Development\, QC\, CMC\, and Process Development leaders grappling with these challenges first-hand. \nIncorporating tracks taking a deep dive into bioassays\, molecular biology\, and analytical chemistry\, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you’re encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo know more about 2nd Annual Gene Therapy Analytical Development please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-gene-therapy-analytical-development/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132440
CREATED:20200826T084509Z
LAST-MODIFIED:20200826T093822Z
UID:26843-1606780800-1607039999@www.pharmajournalist.com
SUMMARY:2nd RNA Editing Summit 2020
DESCRIPTION:RNA Editing is reaching an inflection point and is rapidly being discussed\, invested in and adopted by the industry. \nThis year\, in an all new digital format\, the timely 2nd RNA Editing Summit returns as the only industry led meeting showcasing the recent developments of RNA editing mechanisms and dedicated to realizing the research and therapeutic opportunity of RNA editing as quickly as possible. \n \nThis meeting offers a wealth of relevant content covering everything from basic RNA biology and the fundamentals of RNA editing through to mitigating against off target activity to the plethora of clinical applications. \nJoin industry leaders from the likes of InsideOutBio\, Edigene\, Locano Bio and more to: \n\nHear the current strategies of site directed RNA editing from A – I to C – U to CRISPR based\nUnderstand how to mitigate off target-activity without critically effecting the efficiency of the on target edit in the transcript\nEnsure the safety and stability of your edit whilst maintaining efficiency and safe guard against potential toxic events\nAssess how to develop RNA editing technologies in preclinical models to ensure the system works as intended in the human body\nDelve into the different delivery mechanisms available to ensure the protein molecules that do the editing make it into the cells\nIdentify the latest clinical applications of RNA Editing\, reviewing the structures and functions of ADARs\, CRISPR CAS 13\, APOBEC and their involvements in human diseases\n\nTo know more about 2nd RNA Editing Summit 2020 please click here.
URL:https://www.pharmajournalist.com/event/2nd-rna-editing-summit-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201201
DTEND;VALUE=DATE:20201203
DTSTAMP:20260515T132440
CREATED:20200930T082606Z
LAST-MODIFIED:20200930T082606Z
UID:27304-1606780800-1606953599@www.pharmajournalist.com
SUMMARY:Neuromuscular Drug Development Summit
DESCRIPTION:Validate Clinically Meaningful Endpoints\, Optimize Clinical Trial Design & Compare & Contrast Diverse Approaches to Accelerate the Discovery & Development of Meaningful Treatments for Patients in Need \n \nThe 3rd Neuromuscular Drug Development  Summit presents a unique opportunity to: \n\nUncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen\nHear approaches to optimizing therapeutic efficacy in SMA\, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche\, PTC Therapeutics and John Hopkins University School of Medicine\nAssess emerging neurophysiological methods for more quantitative\, faster readouts and the need to explore digital capture tools to improve therapeutic R&D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD)\nDissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose\, mechanisms of action and endpoints with NMD Pharma and Argenx\nEvaluate the role of biomarkers\, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institut\nHear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1\n\nUniting drug developers and academics from all corners of the world\, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field\, convey lessons learned and network to build long lasting partnerships.
URL:https://www.pharmajournalist.com/event/neuromuscular-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132440
CREATED:20200423T111553Z
LAST-MODIFIED:20200423T111553Z
UID:25220-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:7th Microbiome & Probiotics R&D & Business Collaboration Forum: Europe
DESCRIPTION:In response to COVID-19\, this meeting will be hosted online using the latest digital technology. Network with your peers\, ask questions of the speakers\, and meet with the sponsors from the safety of your home or office. \nThis forum has a long-standing reputation for bringing together leading academic and industry microbiome researchers. Presentations will feature the latest research into the human microbiome as well as effective business and commercialization strategies for new products. \nTopics covered on the agenda include: \n\nIBD\, Colitis\, and Metabolic Diseases\nGut-brain axis\nWomen’s health\nSkin & Cosmeceuticals\nPersonalized nutrition\nBusiness Collaboration – Regulations & Investment\nProbiotics & Prebiotics\nRoundtable discussions\n\nWith dedicated space in the schedule to network\, this conference is the ideal forum to share knowledge and build partnerships. \nVisit the event page to download the full agenda.
URL:https://www.pharmajournalist.com/event/7th-microbiome-probiotics-rd-business-collaboration-forum-europe/
LOCATION:Rotterdam\, The Netherlands
ORGANIZER;CN="Global Engage Ltd.":MAILTO:info@globalengage.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201202
DTEND;VALUE=DATE:20201204
DTSTAMP:20260515T132440
CREATED:20200828T083254Z
LAST-MODIFIED:20200828T083616Z
UID:26875-1606867200-1607039999@www.pharmajournalist.com
SUMMARY:Clinically Validated Digital Therapeutics Summit
DESCRIPTION:As the world opens up to digital health\, now is the time to design\, develop & deliver clinically validated digital therapeutics to patients in need. Back for its 3rd year\, the Clinically Validated Digital Therapeutics Summit will unite more stakeholders than ever before. Explore newcomers in the world of DTx\, showcasing never before shared case studies. This meeting will solely focus on the actionable uses of digital therapeutics to deliver radically improved patient outcomes. \nIntegrating brand new lessons learned from the COVID 19 pandemic\, the 2020 summit will drive the DTx industry forward with case studies that tackle a multitude of disease areas and therapeutic modalities\, from prescription and chronic disease management to care bundles\, concomitant therapy and preventive medicine. Covering the full spectrum\, the 2020 summit will address challenges around clinical trials\, regulatory approval\, reimbursement and value application in healthcare. \nView the Full Event Guide Here.
URL:https://www.pharmajournalist.com/event/clinically-validated-digital-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR